<DOC>
	<DOCNO>NCT01340651</DOCNO>
	<brief_summary>The purpose study determine safety tolerability ruxolitinib ( INCB018424 ) sustain release ( SR ) formulation participant primary myelofibrosis ( PMF ) , post-polycythemia vera MF ( PPV-MF ) , post-essential thrombocythemia MF ( PET-MF ) .</brief_summary>
	<brief_title>Study Ruxolitinib ( INCB018424 ) Sustained Release Formulation Myelofibrosis Patients</brief_title>
	<detailed_description>The study enroll approximately 40 participant PMF , PPV-MF PET-MF . Participants take ruxolitinib SR daily 16 consecutive week transition comparable twice daily dose regimen ruxolitinib use immediate release ( IR ) tablets investigation control Phase 1 , 2 , 3 clinical trial . Participants receive benefit treatment ruxolitinib may continue participation IR tablets time last participant complete Week 36 commercial availability ruxolitinib IR , whichever early . Follow-up occur least 30 day follow last dose ruxolitinib .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<criteria>Participants 18 year age old . Participants must diagnose primary myelofibrosis ( PMF ) , postessential thrombocythemia myelofibrosis ( PPVMF ) , postpolycythemia vera myelofibrosis ( PETMF ) . Participants myelofibrosis require therapy must classify high risk ( 3 prognostic factor ) , intermediate risk level 2 ( 2 prognostic factor ) , intermediate risk level 1 ( 1 prognostic factor ) define International Working Group Myelofibrosis Research Treatment ( IWGMRT ) . Participants must palpable spleen measure 5 cm great costal margin . Participants life expectancy le 6 month . Participants childbearing potential unwilling take appropriate precaution avoid pregnancy father child . Participants inadequate bone marrow reserve . Participants history platelet count &lt; 50,000/μL , platelet transfusion ( ) , absolute neutrophil count &lt; 500/μL month prior Screening . Participants inadequate liver renal function Screening Baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>myelofibrosis</keyword>
	<keyword>myeloproliferative neoplasm</keyword>
	<keyword>PMF</keyword>
	<keyword>PET-MF</keyword>
	<keyword>PPV-MF</keyword>
</DOC>